

Correction to “Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy”

In the above article [Kapur S, VanderSpek SC, Brownlee BA, and Nobrega JN (2003) *J Pharmacol Exp Ther* 305:625–631], a misalignment in Table 2 caused some of the data reported to be displaced. The corrected Table 2 appears below.

The online version of this article has been corrected in departure from print.

The printers regret this error and apologize for any confusion or inconvenience it may have caused.

TABLE 2

Relationship between dose, mode of administration (injection vs. minipump), D₂ occupancy, and plasma levels at different doses of antipsychotics with multiple-dose administration

Drug Group	Delivery Condition	D ₂ Occupancy (Mean ± S.D.)	Plasma Levels (Mean ± S.D.) <i>nM</i>
Haloperidol 0.05 mg/kg	Injection, trough	19 ± 31	<1
	Injection, peak	74 ± 7	1.57 ± 0.42
	Minipump	41 ± 16	<1
0.25 mg/kg	Injection, trough	5 ± 2	<1
	Injection, peak	92 ± 1	11 ± 2.08
	Minipump	69 ± 14	2.40 ± 1.01
Olanzapine 1.5 mg/kg	Injection, trough	16 ± 24	6.67 ± 2.89
	Injection, peak	74 ± 7	251 ± 88.39
	Minipump	38 ± 16	130.83 ± 118.90
7.5 mg/kg	Injection, trough	59 ± 4	<5
	Injection, peak	92 ± 1	3124.33 ± 823.29
	Minipump	75 ± 7	434.33 ± 291.19
Risperidone 1mg/kg	Injection, trough	ND	<1
	Injection, peak	61 ± 3	99.97 ± 33.77
	Minipump	31 ± 9	39.36 ± 24.36
Quetiapine 10 mg/kg	Injection, trough	ND	4.56 ± 2.71
	Injection, peak	ND	469.00 ± 18.96
	Minipump	7 ± 10	108.20 ± 31.88
25 mg/kg	Injection, trough	ND	9.56 ± 7.8
	Injection, peak	69 ± 10	913.01 ± 223.5
	Minipump	25 ± 23	78.79 ± 12.33
Clozapine 7.5 mg/kg	Injection, trough	ND	13 ± 3
	Injection, peak	29 ± 15	1240 ± 438.42
	Minipump	2 ± 22	98 ± 128.83
15 mg/kg	Injection, trough	0.2 ± 20	15 ± 6.35
	Injection, peak	60 ± 12	2969 ± 809.60
	Minipump	ND	98 ± 45.30

ND, no detectable occupancy.